Tamari, R
Mughal, T I
Rondelli, D
Hasserjian, R
Gupta, V
Odenike, O
Fauble, V
Finazzi, G
Pane, F
Mascarenhas, J
Prchal, J
Giralt, S
Hoffman, R
Article History
Received: 26 August 2014
Revised: 16 November 2014
Accepted: 17 November 2014
First Online: 9 February 2015
Competing interests
: VG was a member of the Scientific Advisory Board at Novartis and Incyte, and received research support from Novartis and Incyte. RHa was a member of the Scientific Advisory Board at Incyte. JM received research support from Novartis and Incyte. TIM was a consultant at Novartis and Incyte. OO was a member of the Scientific Advisory Board at Sanofi-Aventis, Incyte, Spectrum Pharmaceuticals, Sunesis Pharmaceuticals and Algeta Pharmaceuticals, and received research support from Eisai Pharmaceuticals and TopoTarget Pharmaceuticals. All other authors declare no conflict of interest.